{"id":93016,"date":"2026-07-21T01:20:15","date_gmt":"2026-07-21T01:20:15","guid":{"rendered":"https:\/\/www.europesays.com\/korea\/93016\/"},"modified":"2026-07-21T01:20:15","modified_gmt":"2026-07-21T01:20:15","slug":"why-samsungs-2-7-trillion-won-deal-signals-its-galaxy-healthcare-push-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/korea\/93016\/","title":{"rendered":"Why Samsung’s 2.7 Trillion Won Deal Signals Its Galaxy Healthcare Push"},"content":{"rendered":"

\"[CAPTIONS] Samsung[CAPTIONS]
\nSamsung Electronics Chairman Lee Jae-yong. Yonhap News<\/p>\n

Samsung Biologics’ move into the largest merger and acquisition in Korea’s pharmaceutical and biotech history is drawing attention to the digital healthcare business that Samsung Group is cultivating as a long-term growth engine. Analysts say Samsung is accelerating efforts to build a vast healthcare ecosystem that connects health management, diagnosis, and hospital treatment based on smartphones and wearable devices with enhanced artificial intelligence (AI) functions.<\/p>\n

Digital Health Market to Reach About $2 Trillion by 2034<\/p>\n

A ‘Blue Ocean’ Larger Than the Entire Semiconductor Market<\/p>\n

\"SamsungSamsung Group affiliates’ major investments in medical and bio-related companies. Seoul Economic Daily<\/p>\n

Samsung Biologics (207940.KS) announced on the 20th that it will acquire PolyPeptide Group, a Switzerland-based global peptide contract development and manufacturing company, for about 2.7 trillion won.<\/p>\n

Samsung Biologics’ “big deal” is the largest M&A in Korea’s pharmaceutical and biotech industry. Through the acquisition, Samsung Biologics will make a full-fledged entry into the peptide drug market, including GLP-1 class drugs regarded as central to treatments for obesity and diabetes.<\/p>\n

Analysts say the deal goes beyond expanding Samsung Biologics’ business scope and connects to Samsung Group’s overall healthcare strategy.<\/p>\n

Digital health is an industry that uses information and communications technology (ICT) and data to improve health management, disease prevention, diagnosis, treatment, and the delivery of medical services. Market research firm Fortune Business Insights estimated the market at $427.2 billion (about 633 trillion won) in 2025, and projects it will reach $2.3512 trillion (3,484 trillion won) by 2034. That is more than double the size of the entire semiconductor market (about $1 trillion, 1,482 trillion won).<\/p>\n

To dominate this market, Samsung is accelerating its digital health push by successively investing in companies spanning medical device and drug production, health data, and hospital-linked platforms.<\/p>\n

\"AA patient undergoing an examination using the premium obstetrics and gynecology ultrasound diagnostic device “HERA Z20.” Photo courtesy of Samsung Medison<\/p>\n

Medical Device Performance Shifts From Hardware to AI<\/p>\n

Samsung Acquires AI Ultrasound Equipment Maker Sonio<\/p>\n

Largest Shareholder of DNA Analysis Firm Predicting Disease<\/p>\n

The industry is focusing on how Samsung’s digital healthcare investments are rapidly expanding into data analysis, AI, and hospital-linked platforms. In particular, analysts note that Samsung’s M&A and equity investments in the digital health sector have been aggressive over the past three years.<\/p>\n

Samsung Medison acquired French medical AI company Sonio in May 2024. Sonio is a company that develops AI software that analyzes fetal ultrasound images to support medical staff in making diagnoses. Samsung Medison secured a 100% stake in Sonio and announced plans to combine AI-based diagnostic support functions with its existing ultrasound equipment.<\/p>\n

This was interpreted as Samsung capturing the trend of competitiveness in the medical device market shifting from hardware to software and AI. In the past, how clear the ultrasound image was determined competitiveness, but going forward, the market is changing in a direction where the ability of AI to read images, detect anomalies, and reduce examination time determines a product’s value.<\/p>\n

Two months after the Sonio acquisition, in July 2024, Samsung also invested in Element Biosciences, a U.S. DNA analysis equipment company. Through additional investment this year, it became Element Biosciences’ largest shareholder.<\/p>\n

Genome analysis technology is used to predict an individual’s disease risk. Genome analysis technology is essential to realizing precision medicine, which designs personalized treatments for individuals.<\/p>\n

\"NurabotNurabot introduced at a Taiwanese hospital. Photo courtesy of TCVGH and Nvidia<\/p>\n

Through this acquisition of PolyPeptide Group by Samsung Biologics, Samsung has expanded its scope into the obesity and diabetes treatment business. This is interpreted as Samsung broadening the range of its healthcare business beyond diagnosis and health management to the actual drug production stage.<\/p>\n

Xealth Acquisition, a Gateway Into Hospital Networks<\/p>\n

Galaxy Connects Health Diagnosis to Medical Institutions<\/p>\n

Xealth, a U.S. digital healthcare company whose acquisition Samsung Electronics (005930.KS) announced in 2025, is the example that most clearly shows Samsung’s strategy. Xealth operates a platform that connects hospitals so they can prescribe and manage digital therapeutics and remote monitoring programs for patients.<\/p>\n

Xealth connects more than 500 hospitals in the U.S. with more than 70 digital health solutions. Through Xealth, Samsung is pursuing a plan to link health data measured from Galaxy smartphones, Galaxy Watch, and Galaxy Ring with medical institutions, subject to patient consent. It is a method that allows treatment and management programs prescribed by hospitals to be used through the Samsung Health application.<\/p>\n

The core of the Xealth acquisition lies not in securing a single specific hospital, but in establishing a channel to enter a broad U.S. hospital network. Samsung has secured a foundation to leap beyond being a wearable device maker to a platform operator that connects medical services and patients.<\/p>\n

\"GalaxyGalaxy Ring. Samsung Electronics<\/p>\n

The industry sees Samsung as seeking to build an ecosystem that collects health information through the Galaxy Watch and Ring, analyzes it with AI, and manages it through Samsung Health. When anomalies are detected, it connects users to hospital care and treatment programs. This means Samsung Health is evolving beyond a simple health management application into a gateway that determines what medical services a user will receive.<\/p>\n

Galaxy Manages the Entire Personal Health Management Process<\/p>\n

Evolving Into a Digital Health ‘Edge Device’<\/p>\n

Some observers say Samsung aims to go beyond being a “gateway” to the digital healthcare market and become a “gatekeeper” that exercises real influence over the market. Based on data generated from Galaxy devices, Samsung would continuously manage users’ health conditions and, when necessary, take on the role of connecting them to appropriate hospitals and treatment programs.<\/p>\n

This is also a strategy to expand the Galaxy ecosystem formed around smartphones into the medical and health management fields. The smartphone market has entered a stage of technological maturity where replacement cycles are lengthening and it is increasingly difficult to differentiate based on device functions alone. In particular, as the pursuit by latecomers such as China intensifies, it is becoming difficult to maintain profitability through simple device sales alone.<\/p>\n

By contrast, if Galaxy devices evolve into edge devices for digital healthcare, the situation changes. Health management services are likely to be used daily, and the effect grows the longer data is accumulated. The more the smartphone, watch, and ring are used together, the more precise the health data that accumulates, and the higher the utilization of Samsung Health and hospital services. Through this, Galaxy can not only increase customer loyalty but also stimulate demand for device replacement.<\/p>\n

For this reason, analysts say Samsung is carving out a breakthrough through aggressive investment in the healthcare sector. It is a strategy to create a sustainable revenue base by building an ecosystem that ties together semiconductors, smartphones, wearables, AI, and bio production technology. “The final destination of the healthcare ‘big deals’ that Samsung continues every year is not simple device sales, but building a platform that encompasses the entire process of personal health management,” an industry official said.<\/p>\n","protected":false},"excerpt":{"rendered":"[CAPTIONS] Samsung Electronics Chairman Lee Jae-yong. Yonhap News Samsung Biologics’ move into the largest merger and acquisition in…\n","protected":false},"author":2,"featured_media":93017,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19],"tags":[5577,48839,48840,48230,127,505,5291,26418,11338],"class_list":["post-93016","post","type-post","status-publish","format-standard","has-post-thumbnail","category-samsung-biologics","tag-digital-healthcare","tag-galaxy-ecosystem","tag-glp-1-peptide-drugs","tag-polypeptide-group","tag-samsung","tag-samsung-biologics","tag-samsung-health","tag-samsung-medison","tag-xealth"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/posts\/93016","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/comments?post=93016"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/posts\/93016\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/media\/93017"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/media?parent=93016"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/categories?post=93016"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/tags?post=93016"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}